nodes	percent_of_prediction	percent_of_DWPC	metapath
Irbesartan—PTGS1—esophageal cancer	0.575	1	CbGaD
Irbesartan—JUN—exocrine gland—esophageal cancer	0.00638	0.11	CbGeAlD
Irbesartan—JUN—neck—esophageal cancer	0.00408	0.0706	CbGeAlD
Irbesartan—UGT1A3—digestive system—esophageal cancer	0.00373	0.0645	CbGeAlD
Irbesartan—AGTR1—neck—esophageal cancer	0.00307	0.0531	CbGeAlD
Irbesartan—EDNRA—bronchus—esophageal cancer	0.003	0.0518	CbGeAlD
Irbesartan—JUN—epithelium—esophageal cancer	0.00278	0.048	CbGeAlD
Irbesartan—JUN—bronchus—esophageal cancer	0.00273	0.0473	CbGeAlD
Irbesartan—EDNRA—trachea—esophageal cancer	0.00269	0.0465	CbGeAlD
Irbesartan—JUN—smooth muscle tissue—esophageal cancer	0.00267	0.0463	CbGeAlD
Irbesartan—JUN—trachea—esophageal cancer	0.00245	0.0424	CbGeAlD
Irbesartan—JUN—digestive system—esophageal cancer	0.00211	0.0365	CbGeAlD
Irbesartan—AGTR1—epithelium—esophageal cancer	0.00209	0.0361	CbGeAlD
Irbesartan—AGTR1—smooth muscle tissue—esophageal cancer	0.00201	0.0348	CbGeAlD
Irbesartan—EDNRA—lung—esophageal cancer	0.00193	0.0334	CbGeAlD
Irbesartan—Olmesartan—ABCC2—esophageal cancer	0.00193	0.486	CrCbGaD
Irbesartan—AGTR1—trachea—esophageal cancer	0.00185	0.032	CbGeAlD
Irbesartan—JUN—lung—esophageal cancer	0.00176	0.0305	CbGeAlD
Irbesartan—AGTR1—lung—esophageal cancer	0.00133	0.023	CbGeAlD
Irbesartan—EDNRA—lymph node—esophageal cancer	0.00132	0.0229	CbGeAlD
Irbesartan—JUN—lymph node—esophageal cancer	0.00121	0.0209	CbGeAlD
Irbesartan—Candesartan—PTGS1—esophageal cancer	0.00114	0.286	CrCbGaD
Irbesartan—PTGS1—epithelium—esophageal cancer	0.000919	0.0159	CbGeAlD
Irbesartan—AGTR1—lymph node—esophageal cancer	0.000908	0.0157	CbGeAlD
Irbesartan—PTGS1—smooth muscle tissue—esophageal cancer	0.000885	0.0153	CbGeAlD
Irbesartan—PTGS1—trachea—esophageal cancer	0.000812	0.0141	CbGeAlD
Irbesartan—CYP1A2—digestive system—esophageal cancer	0.000807	0.014	CbGeAlD
Irbesartan—CYP2C9—digestive system—esophageal cancer	0.000766	0.0132	CbGeAlD
Irbesartan—PTGS1—digestive system—esophageal cancer	0.000699	0.0121	CbGeAlD
Irbesartan—CYP1A2—lung—esophageal cancer	0.000674	0.0117	CbGeAlD
Irbesartan—CYP3A4—digestive system—esophageal cancer	0.000584	0.0101	CbGeAlD
Irbesartan—PTGS1—lung—esophageal cancer	0.000584	0.0101	CbGeAlD
Irbesartan—CYP2D6—digestive system—esophageal cancer	0.000575	0.00994	CbGeAlD
Irbesartan—Candesartan—ABCB1—esophageal cancer	0.000552	0.139	CrCbGaD
Irbesartan—Hyperuricaemia—Methotrexate—esophageal cancer	0.000539	0.00388	CcSEcCtD
Irbesartan—Hot flush—Capecitabine—esophageal cancer	0.000522	0.00376	CcSEcCtD
Irbesartan—Increased appetite—Capecitabine—esophageal cancer	0.000519	0.00374	CcSEcCtD
Irbesartan—Menopausal symptoms—Capecitabine—esophageal cancer	0.000517	0.00372	CcSEcCtD
Irbesartan—Renal impairment—Capecitabine—esophageal cancer	0.000513	0.00369	CcSEcCtD
Irbesartan—Vasculitis—Methotrexate—esophageal cancer	0.000513	0.00369	CcSEcCtD
Irbesartan—Blood uric acid increased—Methotrexate—esophageal cancer	0.00051	0.00367	CcSEcCtD
Irbesartan—Acute coronary syndrome—Cisplatin—esophageal cancer	0.000503	0.00362	CcSEcCtD
Irbesartan—Arthritis—Capecitabine—esophageal cancer	0.000502	0.00361	CcSEcCtD
Irbesartan—Renal failure—Cisplatin—esophageal cancer	0.000501	0.00361	CcSEcCtD
Irbesartan—Myocardial infarction—Cisplatin—esophageal cancer	0.0005	0.0036	CcSEcCtD
Irbesartan—Cerebrovascular accident—Capecitabine—esophageal cancer	0.000498	0.00358	CcSEcCtD
Irbesartan—Conjunctivitis—Cisplatin—esophageal cancer	0.000496	0.00357	CcSEcCtD
Irbesartan—Hyponatraemia—Capecitabine—esophageal cancer	0.00049	0.00353	CcSEcCtD
Irbesartan—Hepatobiliary disease—Cisplatin—esophageal cancer	0.000482	0.00347	CcSEcCtD
Irbesartan—Face oedema—Capecitabine—esophageal cancer	0.000471	0.00339	CcSEcCtD
Irbesartan—Aplastic anaemia—Methotrexate—esophageal cancer	0.00047	0.00338	CcSEcCtD
Irbesartan—Bradycardia—Cisplatin—esophageal cancer	0.000466	0.00336	CcSEcCtD
Irbesartan—Mood swings—Capecitabine—esophageal cancer	0.000462	0.00333	CcSEcCtD
Irbesartan—Ecchymosis—Methotrexate—esophageal cancer	0.000452	0.00326	CcSEcCtD
Irbesartan—Urinary tract disorder—Cisplatin—esophageal cancer	0.000452	0.00326	CcSEcCtD
Irbesartan—Liver function test abnormal—Capecitabine—esophageal cancer	0.00045	0.00324	CcSEcCtD
Irbesartan—Connective tissue disorder—Cisplatin—esophageal cancer	0.00045	0.00324	CcSEcCtD
Irbesartan—Urethral disorder—Cisplatin—esophageal cancer	0.000449	0.00323	CcSEcCtD
Irbesartan—Orthostatic hypotension—Capecitabine—esophageal cancer	0.000446	0.00321	CcSEcCtD
Irbesartan—Abdominal pain upper—Capecitabine—esophageal cancer	0.000446	0.00321	CcSEcCtD
Irbesartan—Pulmonary oedema—Methotrexate—esophageal cancer	0.000445	0.00321	CcSEcCtD
Irbesartan—Hypokalaemia—Capecitabine—esophageal cancer	0.000444	0.0032	CcSEcCtD
Irbesartan—Visual impairment—Cisplatin—esophageal cancer	0.000441	0.00318	CcSEcCtD
Irbesartan—Breast disorder—Capecitabine—esophageal cancer	0.000441	0.00317	CcSEcCtD
Irbesartan—Toxic epidermal necrolysis—Capecitabine—esophageal cancer	0.000439	0.00316	CcSEcCtD
Irbesartan—Nasopharyngitis—Capecitabine—esophageal cancer	0.000436	0.00314	CcSEcCtD
Irbesartan—Muscular weakness—Capecitabine—esophageal cancer	0.00043	0.0031	CcSEcCtD
Irbesartan—Tinnitus—Cisplatin—esophageal cancer	0.000427	0.00307	CcSEcCtD
Irbesartan—Flushing—Cisplatin—esophageal cancer	0.000425	0.00306	CcSEcCtD
Irbesartan—Cardiac disorder—Cisplatin—esophageal cancer	0.000425	0.00306	CcSEcCtD
Irbesartan—Abdominal distension—Capecitabine—esophageal cancer	0.000425	0.00306	CcSEcCtD
Irbesartan—Asthma—Capecitabine—esophageal cancer	0.000422	0.00304	CcSEcCtD
Irbesartan—Dysphagia—Capecitabine—esophageal cancer	0.000422	0.00304	CcSEcCtD
Irbesartan—Influenza—Capecitabine—esophageal cancer	0.000422	0.00304	CcSEcCtD
Irbesartan—Diabetes mellitus—Methotrexate—esophageal cancer	0.000418	0.00301	CcSEcCtD
Irbesartan—Photosensitivity—Methotrexate—esophageal cancer	0.000414	0.00298	CcSEcCtD
Irbesartan—Immune system disorder—Cisplatin—esophageal cancer	0.000414	0.00298	CcSEcCtD
Irbesartan—Mediastinal disorder—Cisplatin—esophageal cancer	0.000413	0.00297	CcSEcCtD
Irbesartan—Angina pectoris—Capecitabine—esophageal cancer	0.000411	0.00296	CcSEcCtD
Irbesartan—Arrhythmia—Cisplatin—esophageal cancer	0.000409	0.00295	CcSEcCtD
Irbesartan—PTGS1—lymph node—esophageal cancer	0.000399	0.00691	CbGeAlD
Irbesartan—Malnutrition—Cisplatin—esophageal cancer	0.000399	0.00287	CcSEcCtD
Irbesartan—Erythema—Cisplatin—esophageal cancer	0.000399	0.00287	CcSEcCtD
Irbesartan—Neutropenia—Capecitabine—esophageal cancer	0.000394	0.00284	CcSEcCtD
Irbesartan—Flatulence—Cisplatin—esophageal cancer	0.000393	0.00283	CcSEcCtD
Irbesartan—Upper respiratory tract infection—Capecitabine—esophageal cancer	0.000392	0.00282	CcSEcCtD
Irbesartan—Photosensitivity reaction—Capecitabine—esophageal cancer	0.000385	0.00277	CcSEcCtD
Irbesartan—Weight increased—Capecitabine—esophageal cancer	0.000384	0.00276	CcSEcCtD
Irbesartan—Visual disturbance—Methotrexate—esophageal cancer	0.000383	0.00276	CcSEcCtD
Irbesartan—Muscle spasms—Cisplatin—esophageal cancer	0.000383	0.00276	CcSEcCtD
Irbesartan—Hyperglycaemia—Capecitabine—esophageal cancer	0.00038	0.00274	CcSEcCtD
Irbesartan—Pneumonia—Capecitabine—esophageal cancer	0.000378	0.00272	CcSEcCtD
Irbesartan—Vision blurred—Cisplatin—esophageal cancer	0.000376	0.0027	CcSEcCtD
Irbesartan—Tremor—Cisplatin—esophageal cancer	0.000373	0.00269	CcSEcCtD
Irbesartan—Acute coronary syndrome—Capecitabine—esophageal cancer	0.000371	0.00267	CcSEcCtD
Irbesartan—Cerebrovascular accident—Methotrexate—esophageal cancer	0.000371	0.00267	CcSEcCtD
Irbesartan—Ill-defined disorder—Cisplatin—esophageal cancer	0.00037	0.00266	CcSEcCtD
Irbesartan—Renal failure—Capecitabine—esophageal cancer	0.00037	0.00266	CcSEcCtD
Irbesartan—Myocardial infarction—Capecitabine—esophageal cancer	0.000369	0.00265	CcSEcCtD
Irbesartan—Anaemia—Cisplatin—esophageal cancer	0.000368	0.00265	CcSEcCtD
Irbesartan—Jaundice—Capecitabine—esophageal cancer	0.000367	0.00264	CcSEcCtD
Irbesartan—Conjunctivitis—Capecitabine—esophageal cancer	0.000365	0.00263	CcSEcCtD
Irbesartan—Urinary tract infection—Capecitabine—esophageal cancer	0.000365	0.00263	CcSEcCtD
Irbesartan—Malaise—Cisplatin—esophageal cancer	0.000359	0.00259	CcSEcCtD
Irbesartan—Leukopenia—Cisplatin—esophageal cancer	0.000357	0.00257	CcSEcCtD
Irbesartan—Hepatobiliary disease—Capecitabine—esophageal cancer	0.000356	0.00256	CcSEcCtD
Irbesartan—Losartan—ABCB1—esophageal cancer	0.000356	0.0895	CrCbGaD
Irbesartan—Epistaxis—Capecitabine—esophageal cancer	0.000355	0.00255	CcSEcCtD
Irbesartan—Agranulocytosis—Capecitabine—esophageal cancer	0.000351	0.00253	CcSEcCtD
Irbesartan—Mood swings—Methotrexate—esophageal cancer	0.000344	0.00248	CcSEcCtD
Irbesartan—Bradycardia—Capecitabine—esophageal cancer	0.000344	0.00247	CcSEcCtD
Irbesartan—Myalgia—Cisplatin—esophageal cancer	0.000339	0.00244	CcSEcCtD
Irbesartan—Rhinitis—Capecitabine—esophageal cancer	0.000338	0.00244	CcSEcCtD
Irbesartan—Anxiety—Cisplatin—esophageal cancer	0.000338	0.00243	CcSEcCtD
Irbesartan—Hepatitis—Capecitabine—esophageal cancer	0.000338	0.00243	CcSEcCtD
Irbesartan—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.000337	0.00243	CcSEcCtD
Irbesartan—Hypoaesthesia—Capecitabine—esophageal cancer	0.000336	0.00242	CcSEcCtD
Irbesartan—Liver function test abnormal—Methotrexate—esophageal cancer	0.000335	0.00241	CcSEcCtD
Irbesartan—Discomfort—Cisplatin—esophageal cancer	0.000335	0.00241	CcSEcCtD
Irbesartan—Pharyngitis—Capecitabine—esophageal cancer	0.000335	0.00241	CcSEcCtD
Irbesartan—Urinary tract disorder—Capecitabine—esophageal cancer	0.000333	0.0024	CcSEcCtD
Irbesartan—Oedema peripheral—Capecitabine—esophageal cancer	0.000333	0.00239	CcSEcCtD
Irbesartan—Connective tissue disorder—Capecitabine—esophageal cancer	0.000332	0.00239	CcSEcCtD
Irbesartan—Urethral disorder—Capecitabine—esophageal cancer	0.000331	0.00238	CcSEcCtD
Irbesartan—Breast disorder—Methotrexate—esophageal cancer	0.000328	0.00236	CcSEcCtD
Irbesartan—Toxic epidermal necrolysis—Methotrexate—esophageal cancer	0.000327	0.00235	CcSEcCtD
Irbesartan—Oedema—Cisplatin—esophageal cancer	0.000325	0.00234	CcSEcCtD
Irbesartan—Anaphylactic shock—Cisplatin—esophageal cancer	0.000325	0.00234	CcSEcCtD
Irbesartan—Visual impairment—Capecitabine—esophageal cancer	0.000325	0.00234	CcSEcCtD
Irbesartan—Infection—Cisplatin—esophageal cancer	0.000323	0.00233	CcSEcCtD
Irbesartan—Nervous system disorder—Cisplatin—esophageal cancer	0.000319	0.0023	CcSEcCtD
Irbesartan—Thrombocytopenia—Cisplatin—esophageal cancer	0.000319	0.00229	CcSEcCtD
Irbesartan—Tachycardia—Cisplatin—esophageal cancer	0.000318	0.00229	CcSEcCtD
Irbesartan—Skin disorder—Cisplatin—esophageal cancer	0.000316	0.00228	CcSEcCtD
Irbesartan—Tinnitus—Capecitabine—esophageal cancer	0.000315	0.00227	CcSEcCtD
Irbesartan—Hyperhidrosis—Cisplatin—esophageal cancer	0.000315	0.00226	CcSEcCtD
Irbesartan—Asthma—Methotrexate—esophageal cancer	0.000314	0.00226	CcSEcCtD
Irbesartan—Flushing—Capecitabine—esophageal cancer	0.000313	0.00226	CcSEcCtD
Irbesartan—Cardiac disorder—Capecitabine—esophageal cancer	0.000313	0.00226	CcSEcCtD
Irbesartan—Anorexia—Cisplatin—esophageal cancer	0.00031	0.00223	CcSEcCtD
Irbesartan—Pancreatitis—Methotrexate—esophageal cancer	0.000308	0.00222	CcSEcCtD
Irbesartan—Angiopathy—Capecitabine—esophageal cancer	0.000306	0.0022	CcSEcCtD
Irbesartan—Immune system disorder—Capecitabine—esophageal cancer	0.000305	0.0022	CcSEcCtD
Irbesartan—Mediastinal disorder—Capecitabine—esophageal cancer	0.000304	0.00219	CcSEcCtD
Irbesartan—Hypotension—Cisplatin—esophageal cancer	0.000304	0.00219	CcSEcCtD
Irbesartan—Chills—Capecitabine—esophageal cancer	0.000303	0.00218	CcSEcCtD
Irbesartan—Arrhythmia—Capecitabine—esophageal cancer	0.000302	0.00217	CcSEcCtD
Irbesartan—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.000296	0.00213	CcSEcCtD
Irbesartan—Erythema—Capecitabine—esophageal cancer	0.000294	0.00212	CcSEcCtD
Irbesartan—Malnutrition—Capecitabine—esophageal cancer	0.000294	0.00212	CcSEcCtD
Irbesartan—Neutropenia—Methotrexate—esophageal cancer	0.000294	0.00211	CcSEcCtD
Irbesartan—Paraesthesia—Cisplatin—esophageal cancer	0.000292	0.0021	CcSEcCtD
Irbesartan—Upper respiratory tract infection—Methotrexate—esophageal cancer	0.000292	0.0021	CcSEcCtD
Irbesartan—Dyspnoea—Cisplatin—esophageal cancer	0.00029	0.00209	CcSEcCtD
Irbesartan—Flatulence—Capecitabine—esophageal cancer	0.00029	0.00208	CcSEcCtD
Irbesartan—Dysgeusia—Capecitabine—esophageal cancer	0.000288	0.00207	CcSEcCtD
Irbesartan—Photosensitivity reaction—Methotrexate—esophageal cancer	0.000287	0.00206	CcSEcCtD
Irbesartan—Decreased appetite—Cisplatin—esophageal cancer	0.000283	0.00204	CcSEcCtD
Irbesartan—Muscle spasms—Capecitabine—esophageal cancer	0.000283	0.00203	CcSEcCtD
Irbesartan—Pneumonia—Methotrexate—esophageal cancer	0.000282	0.00203	CcSEcCtD
Irbesartan—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.000281	0.00202	CcSEcCtD
Irbesartan—Pain—Cisplatin—esophageal cancer	0.000278	0.002	CcSEcCtD
Irbesartan—Vision blurred—Capecitabine—esophageal cancer	0.000277	0.00199	CcSEcCtD
Irbesartan—Tremor—Capecitabine—esophageal cancer	0.000275	0.00198	CcSEcCtD
Irbesartan—Renal failure—Methotrexate—esophageal cancer	0.000275	0.00198	CcSEcCtD
Irbesartan—Ill-defined disorder—Capecitabine—esophageal cancer	0.000273	0.00196	CcSEcCtD
Irbesartan—Conjunctivitis—Methotrexate—esophageal cancer	0.000272	0.00196	CcSEcCtD
Irbesartan—Anaemia—Capecitabine—esophageal cancer	0.000272	0.00196	CcSEcCtD
Irbesartan—Feeling abnormal—Cisplatin—esophageal cancer	0.000268	0.00193	CcSEcCtD
Irbesartan—Malaise—Capecitabine—esophageal cancer	0.000265	0.00191	CcSEcCtD
Irbesartan—Hepatobiliary disease—Methotrexate—esophageal cancer	0.000265	0.00191	CcSEcCtD
Irbesartan—Epistaxis—Methotrexate—esophageal cancer	0.000264	0.0019	CcSEcCtD
Irbesartan—Vertigo—Capecitabine—esophageal cancer	0.000264	0.0019	CcSEcCtD
Irbesartan—Syncope—Capecitabine—esophageal cancer	0.000264	0.0019	CcSEcCtD
Irbesartan—Leukopenia—Capecitabine—esophageal cancer	0.000263	0.00189	CcSEcCtD
Irbesartan—Agranulocytosis—Methotrexate—esophageal cancer	0.000261	0.00188	CcSEcCtD
Irbesartan—Loss of consciousness—Capecitabine—esophageal cancer	0.000258	0.00186	CcSEcCtD
Irbesartan—Body temperature increased—Cisplatin—esophageal cancer	0.000257	0.00185	CcSEcCtD
Irbesartan—Cough—Capecitabine—esophageal cancer	0.000256	0.00185	CcSEcCtD
Irbesartan—Hypertension—Capecitabine—esophageal cancer	0.000254	0.00183	CcSEcCtD
Irbesartan—Hepatitis—Methotrexate—esophageal cancer	0.000251	0.00181	CcSEcCtD
Irbesartan—Chest pain—Capecitabine—esophageal cancer	0.00025	0.0018	CcSEcCtD
Irbesartan—Myalgia—Capecitabine—esophageal cancer	0.00025	0.0018	CcSEcCtD
Irbesartan—Arthralgia—Capecitabine—esophageal cancer	0.00025	0.0018	CcSEcCtD
Irbesartan—Pharyngitis—Methotrexate—esophageal cancer	0.000249	0.0018	CcSEcCtD
Irbesartan—Anxiety—Capecitabine—esophageal cancer	0.000249	0.00179	CcSEcCtD
Irbesartan—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.000248	0.00179	CcSEcCtD
Irbesartan—Urinary tract disorder—Methotrexate—esophageal cancer	0.000248	0.00179	CcSEcCtD
Irbesartan—Discomfort—Capecitabine—esophageal cancer	0.000247	0.00178	CcSEcCtD
Irbesartan—Urethral disorder—Methotrexate—esophageal cancer	0.000246	0.00177	CcSEcCtD
Irbesartan—Dry mouth—Capecitabine—esophageal cancer	0.000245	0.00176	CcSEcCtD
Irbesartan—Visual impairment—Methotrexate—esophageal cancer	0.000242	0.00174	CcSEcCtD
Irbesartan—Oedema—Capecitabine—esophageal cancer	0.00024	0.00173	CcSEcCtD
Irbesartan—Hypersensitivity—Cisplatin—esophageal cancer	0.00024	0.00173	CcSEcCtD
Irbesartan—Infection—Capecitabine—esophageal cancer	0.000238	0.00172	CcSEcCtD
Irbesartan—Shock—Capecitabine—esophageal cancer	0.000236	0.0017	CcSEcCtD
Irbesartan—Nervous system disorder—Capecitabine—esophageal cancer	0.000235	0.00169	CcSEcCtD
Irbesartan—Thrombocytopenia—Capecitabine—esophageal cancer	0.000235	0.00169	CcSEcCtD
Irbesartan—Tinnitus—Methotrexate—esophageal cancer	0.000234	0.00169	CcSEcCtD
Irbesartan—Tachycardia—Capecitabine—esophageal cancer	0.000234	0.00169	CcSEcCtD
Irbesartan—Asthenia—Cisplatin—esophageal cancer	0.000233	0.00168	CcSEcCtD
Irbesartan—Cardiac disorder—Methotrexate—esophageal cancer	0.000233	0.00168	CcSEcCtD
Irbesartan—Skin disorder—Capecitabine—esophageal cancer	0.000233	0.00168	CcSEcCtD
Irbesartan—Hyperhidrosis—Capecitabine—esophageal cancer	0.000232	0.00167	CcSEcCtD
Irbesartan—Anorexia—Capecitabine—esophageal cancer	0.000229	0.00165	CcSEcCtD
Irbesartan—Angiopathy—Methotrexate—esophageal cancer	0.000228	0.00164	CcSEcCtD
Irbesartan—Immune system disorder—Methotrexate—esophageal cancer	0.000227	0.00163	CcSEcCtD
Irbesartan—Mediastinal disorder—Methotrexate—esophageal cancer	0.000226	0.00163	CcSEcCtD
Irbesartan—Chills—Methotrexate—esophageal cancer	0.000225	0.00162	CcSEcCtD
Irbesartan—Hypotension—Capecitabine—esophageal cancer	0.000224	0.00161	CcSEcCtD
Irbesartan—Diarrhoea—Cisplatin—esophageal cancer	0.000223	0.0016	CcSEcCtD
Irbesartan—Malnutrition—Methotrexate—esophageal cancer	0.000219	0.00157	CcSEcCtD
Irbesartan—Erythema—Methotrexate—esophageal cancer	0.000219	0.00157	CcSEcCtD
Irbesartan—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.000218	0.00157	CcSEcCtD
Irbesartan—Paraesthesia—Capecitabine—esophageal cancer	0.000215	0.00155	CcSEcCtD
Irbesartan—Dysgeusia—Methotrexate—esophageal cancer	0.000214	0.00154	CcSEcCtD
Irbesartan—Dyspnoea—Capecitabine—esophageal cancer	0.000214	0.00154	CcSEcCtD
Irbesartan—Dyspepsia—Capecitabine—esophageal cancer	0.000211	0.00152	CcSEcCtD
Irbesartan—Decreased appetite—Capecitabine—esophageal cancer	0.000208	0.0015	CcSEcCtD
Irbesartan—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.000207	0.00149	CcSEcCtD
Irbesartan—Vomiting—Cisplatin—esophageal cancer	0.000207	0.00149	CcSEcCtD
Irbesartan—Fatigue—Capecitabine—esophageal cancer	0.000207	0.00149	CcSEcCtD
Irbesartan—Vision blurred—Methotrexate—esophageal cancer	0.000206	0.00148	CcSEcCtD
Irbesartan—Rash—Cisplatin—esophageal cancer	0.000205	0.00148	CcSEcCtD
Irbesartan—Pain—Capecitabine—esophageal cancer	0.000205	0.00148	CcSEcCtD
Irbesartan—Constipation—Capecitabine—esophageal cancer	0.000205	0.00148	CcSEcCtD
Irbesartan—Dermatitis—Cisplatin—esophageal cancer	0.000205	0.00148	CcSEcCtD
Irbesartan—Ill-defined disorder—Methotrexate—esophageal cancer	0.000203	0.00146	CcSEcCtD
Irbesartan—Anaemia—Methotrexate—esophageal cancer	0.000202	0.00146	CcSEcCtD
Irbesartan—Feeling abnormal—Capecitabine—esophageal cancer	0.000198	0.00142	CcSEcCtD
Irbesartan—Malaise—Methotrexate—esophageal cancer	0.000197	0.00142	CcSEcCtD
Irbesartan—Vertigo—Methotrexate—esophageal cancer	0.000197	0.00141	CcSEcCtD
Irbesartan—Gastrointestinal pain—Capecitabine—esophageal cancer	0.000196	0.00141	CcSEcCtD
Irbesartan—Leukopenia—Methotrexate—esophageal cancer	0.000196	0.00141	CcSEcCtD
Irbesartan—Nausea—Cisplatin—esophageal cancer	0.000193	0.00139	CcSEcCtD
Irbesartan—Cough—Methotrexate—esophageal cancer	0.000191	0.00137	CcSEcCtD
Irbesartan—Urticaria—Capecitabine—esophageal cancer	0.000191	0.00137	CcSEcCtD
Irbesartan—Abdominal pain—Capecitabine—esophageal cancer	0.00019	0.00136	CcSEcCtD
Irbesartan—Body temperature increased—Capecitabine—esophageal cancer	0.00019	0.00136	CcSEcCtD
Irbesartan—Myalgia—Methotrexate—esophageal cancer	0.000186	0.00134	CcSEcCtD
Irbesartan—Arthralgia—Methotrexate—esophageal cancer	0.000186	0.00134	CcSEcCtD
Irbesartan—Chest pain—Methotrexate—esophageal cancer	0.000186	0.00134	CcSEcCtD
Irbesartan—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.000185	0.00133	CcSEcCtD
Irbesartan—Discomfort—Methotrexate—esophageal cancer	0.000184	0.00132	CcSEcCtD
Irbesartan—Anaphylactic shock—Methotrexate—esophageal cancer	0.000179	0.00129	CcSEcCtD
Irbesartan—Infection—Methotrexate—esophageal cancer	0.000177	0.00128	CcSEcCtD
Irbesartan—Hypersensitivity—Capecitabine—esophageal cancer	0.000177	0.00127	CcSEcCtD
Irbesartan—Nervous system disorder—Methotrexate—esophageal cancer	0.000175	0.00126	CcSEcCtD
Irbesartan—Thrombocytopenia—Methotrexate—esophageal cancer	0.000175	0.00126	CcSEcCtD
Irbesartan—Skin disorder—Methotrexate—esophageal cancer	0.000173	0.00125	CcSEcCtD
Irbesartan—Hyperhidrosis—Methotrexate—esophageal cancer	0.000173	0.00124	CcSEcCtD
Irbesartan—Asthenia—Capecitabine—esophageal cancer	0.000172	0.00124	CcSEcCtD
Irbesartan—Anorexia—Methotrexate—esophageal cancer	0.00017	0.00123	CcSEcCtD
Irbesartan—Pruritus—Capecitabine—esophageal cancer	0.00017	0.00122	CcSEcCtD
Irbesartan—Hypotension—Methotrexate—esophageal cancer	0.000167	0.0012	CcSEcCtD
Irbesartan—Diarrhoea—Capecitabine—esophageal cancer	0.000164	0.00118	CcSEcCtD
Irbesartan—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.000163	0.00117	CcSEcCtD
Irbesartan—Paraesthesia—Methotrexate—esophageal cancer	0.00016	0.00115	CcSEcCtD
Irbesartan—Dyspnoea—Methotrexate—esophageal cancer	0.000159	0.00115	CcSEcCtD
Irbesartan—Somnolence—Methotrexate—esophageal cancer	0.000159	0.00114	CcSEcCtD
Irbesartan—Dizziness—Capecitabine—esophageal cancer	0.000159	0.00114	CcSEcCtD
Irbesartan—Dyspepsia—Methotrexate—esophageal cancer	0.000157	0.00113	CcSEcCtD
Irbesartan—Decreased appetite—Methotrexate—esophageal cancer	0.000155	0.00112	CcSEcCtD
Irbesartan—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.000154	0.00111	CcSEcCtD
Irbesartan—Fatigue—Methotrexate—esophageal cancer	0.000154	0.00111	CcSEcCtD
Irbesartan—Pain—Methotrexate—esophageal cancer	0.000153	0.0011	CcSEcCtD
Irbesartan—Vomiting—Capecitabine—esophageal cancer	0.000152	0.0011	CcSEcCtD
Irbesartan—Rash—Capecitabine—esophageal cancer	0.000151	0.00109	CcSEcCtD
Irbesartan—Dermatitis—Capecitabine—esophageal cancer	0.000151	0.00109	CcSEcCtD
Irbesartan—Headache—Capecitabine—esophageal cancer	0.00015	0.00108	CcSEcCtD
Irbesartan—Feeling abnormal—Methotrexate—esophageal cancer	0.000147	0.00106	CcSEcCtD
Irbesartan—Gastrointestinal pain—Methotrexate—esophageal cancer	0.000146	0.00105	CcSEcCtD
Irbesartan—Nausea—Capecitabine—esophageal cancer	0.000142	0.00103	CcSEcCtD
Irbesartan—Urticaria—Methotrexate—esophageal cancer	0.000142	0.00102	CcSEcCtD
Irbesartan—Abdominal pain—Methotrexate—esophageal cancer	0.000141	0.00102	CcSEcCtD
Irbesartan—Body temperature increased—Methotrexate—esophageal cancer	0.000141	0.00102	CcSEcCtD
Irbesartan—Hypersensitivity—Methotrexate—esophageal cancer	0.000132	0.000947	CcSEcCtD
Irbesartan—Asthenia—Methotrexate—esophageal cancer	0.000128	0.000922	CcSEcCtD
Irbesartan—Pruritus—Methotrexate—esophageal cancer	0.000126	0.000909	CcSEcCtD
Irbesartan—Diarrhoea—Methotrexate—esophageal cancer	0.000122	0.000879	CcSEcCtD
Irbesartan—Dizziness—Methotrexate—esophageal cancer	0.000118	0.00085	CcSEcCtD
Irbesartan—Vomiting—Methotrexate—esophageal cancer	0.000114	0.000817	CcSEcCtD
Irbesartan—Rash—Methotrexate—esophageal cancer	0.000113	0.00081	CcSEcCtD
Irbesartan—Dermatitis—Methotrexate—esophageal cancer	0.000112	0.00081	CcSEcCtD
Irbesartan—Headache—Methotrexate—esophageal cancer	0.000112	0.000805	CcSEcCtD
Irbesartan—Nausea—Methotrexate—esophageal cancer	0.000106	0.000763	CcSEcCtD
Irbesartan—JUN—Signaling Pathways—NOTCH3—esophageal cancer	2.52e-05	0.000113	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—GHRL—esophageal cancer	2.52e-05	0.000113	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—FBXW7—esophageal cancer	2.48e-05	0.000111	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—GSTT1—esophageal cancer	2.41e-05	0.000108	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—CDKN1A—esophageal cancer	2.41e-05	0.000108	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—CYP2A6—esophageal cancer	2.39e-05	0.000107	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—NOTCH1—esophageal cancer	2.39e-05	0.000107	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	2.38e-05	0.000106	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—CA2—esophageal cancer	2.34e-05	0.000105	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—ADH1B—esophageal cancer	2.33e-05	0.000104	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—CA2—esophageal cancer	2.32e-05	0.000104	CbGpPWpGaD
Irbesartan—JUN—Immune System—TLR4—esophageal cancer	2.3e-05	0.000103	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—EP300—esophageal cancer	2.29e-05	0.000102	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—PTGS1—esophageal cancer	2.28e-05	0.000102	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	2.27e-05	0.000101	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—ENO1—esophageal cancer	2.26e-05	0.000101	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—NOTCH2—esophageal cancer	2.26e-05	0.000101	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—PSME2—esophageal cancer	2.23e-05	9.96e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—PSME1—esophageal cancer	2.23e-05	9.96e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—TYMP—esophageal cancer	2.22e-05	9.94e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—PLCE1—esophageal cancer	2.18e-05	9.74e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—ADH7—esophageal cancer	2.18e-05	9.74e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—CA1—esophageal cancer	2.17e-05	9.7e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—SLC10A2—esophageal cancer	2.17e-05	9.7e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—CYP26A1—esophageal cancer	2.16e-05	9.67e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—CREBBP—esophageal cancer	2.16e-05	9.67e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—PLCE1—esophageal cancer	2.16e-05	9.65e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—ADH7—esophageal cancer	2.16e-05	9.65e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	2.14e-05	9.54e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—EGFR—esophageal cancer	2.13e-05	9.5e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—ALOX15—esophageal cancer	2.11e-05	9.42e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—HIF1A—esophageal cancer	2.08e-05	9.29e-05	CbGpPWpGaD
Irbesartan—EDNRA—GPCR downstream signaling—PIK3CA—esophageal cancer	2.03e-05	9.08e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—TPI1—esophageal cancer	2.01e-05	8.99e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—GSTO1—esophageal cancer	2.01e-05	8.99e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—TGFBR2—esophageal cancer	2e-05	8.96e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—KDR—esophageal cancer	1.99e-05	8.88e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—CA2—esophageal cancer	1.99e-05	8.87e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—CASP8—esophageal cancer	1.97e-05	8.8e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—SLC52A3—esophageal cancer	1.97e-05	8.8e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—BLVRB—esophageal cancer	1.97e-05	8.8e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—CREBBP—esophageal cancer	1.96e-05	8.77e-05	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—EGFR—esophageal cancer	1.96e-05	8.74e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	1.95e-05	8.7e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	1.94e-05	8.67e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—NOS3—esophageal cancer	1.94e-05	8.65e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—ALDOB—esophageal cancer	1.93e-05	8.62e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—CYP1B1—esophageal cancer	1.92e-05	8.6e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—ADH1B—esophageal cancer	1.91e-05	8.54e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—SMAD4—esophageal cancer	1.9e-05	8.48e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—ADH1B—esophageal cancer	1.89e-05	8.46e-05	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—CREBBP—esophageal cancer	1.88e-05	8.4e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—NOTCH1—esophageal cancer	1.87e-05	8.37e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—GAPDH—esophageal cancer	1.86e-05	8.29e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—ADH7—esophageal cancer	1.85e-05	8.25e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—PLCE1—esophageal cancer	1.85e-05	8.25e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—PIK3CA—esophageal cancer	1.85e-05	8.24e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—CRABP1—esophageal cancer	1.84e-05	8.22e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—TYMP—esophageal cancer	1.83e-05	8.16e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	1.82e-05	8.15e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—ERBB2—esophageal cancer	1.81e-05	8.1e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—TYMP—esophageal cancer	1.81e-05	8.09e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—CYP19A1—esophageal cancer	1.81e-05	8.08e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—CYP26A1—esophageal cancer	1.78e-05	7.94e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—CYP26A1—esophageal cancer	1.76e-05	7.87e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—GNG7—esophageal cancer	1.75e-05	7.82e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—ALOX15—esophageal cancer	1.73e-05	7.73e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—ALOX15—esophageal cancer	1.72e-05	7.67e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—CREBBP—esophageal cancer	1.7e-05	7.59e-05	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—PIK3CA—esophageal cancer	1.7e-05	7.58e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—BCL2—esophageal cancer	1.69e-05	7.56e-05	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—NOS3—esophageal cancer	1.68e-05	7.52e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—SLC10A2—esophageal cancer	1.68e-05	7.49e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—CA1—esophageal cancer	1.68e-05	7.49e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—EGFR—esophageal cancer	1.67e-05	7.45e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—TPI1—esophageal cancer	1.65e-05	7.38e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—GSTO1—esophageal cancer	1.65e-05	7.38e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—HMOX1—esophageal cancer	1.65e-05	7.38e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—ERBB2—esophageal cancer	1.64e-05	7.34e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—ALDH2—esophageal cancer	1.64e-05	7.33e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—GSTO1—esophageal cancer	1.64e-05	7.31e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—TPI1—esophageal cancer	1.64e-05	7.31e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	1.62e-05	7.24e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—ADH1B—esophageal cancer	1.62e-05	7.23e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—CCND1—esophageal cancer	1.6e-05	7.15e-05	CbGpPWpGaD
Irbesartan—AGTR1—GPCR downstream signaling—PIK3CA—esophageal cancer	1.59e-05	7.12e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—ABCB1—esophageal cancer	1.58e-05	7.08e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—ALDOB—esophageal cancer	1.58e-05	7.07e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—ALDOB—esophageal cancer	1.57e-05	7.01e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—GSTT1—esophageal cancer	1.56e-05	6.97e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—HIF1A—esophageal cancer	1.55e-05	6.94e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—CDKN1A—esophageal cancer	1.55e-05	6.92e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—TYMP—esophageal cancer	1.55e-05	6.91e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—CYP2A6—esophageal cancer	1.54e-05	6.89e-05	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—PTGS2—esophageal cancer	1.54e-05	6.88e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	1.54e-05	6.86e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—CA2—esophageal cancer	1.53e-05	6.85e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—GAPDH—esophageal cancer	1.52e-05	6.81e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—NOS3—esophageal cancer	1.52e-05	6.79e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—GAPDH—esophageal cancer	1.51e-05	6.75e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—CRABP1—esophageal cancer	1.51e-05	6.75e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—CYP26A1—esophageal cancer	1.5e-05	6.72e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—CRABP1—esophageal cancer	1.5e-05	6.69e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—KDR—esophageal cancer	1.49e-05	6.64e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—EP300—esophageal cancer	1.47e-05	6.58e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—ALOX15—esophageal cancer	1.47e-05	6.55e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—ENO1—esophageal cancer	1.46e-05	6.53e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—PTGS1—esophageal cancer	1.46e-05	6.53e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—PIK3CA—esophageal cancer	1.45e-05	6.47e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—PSME1—esophageal cancer	1.44e-05	6.43e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—PSME2—esophageal cancer	1.44e-05	6.43e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—GNG7—esophageal cancer	1.44e-05	6.42e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PLCE1—esophageal cancer	1.42e-05	6.37e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—ADH7—esophageal cancer	1.42e-05	6.37e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—GNG7—esophageal cancer	1.42e-05	6.36e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—ERBB2—esophageal cancer	1.42e-05	6.35e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—CDKN1A—esophageal cancer	1.4e-05	6.27e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—GSTO1—esophageal cancer	1.4e-05	6.25e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—TPI1—esophageal cancer	1.4e-05	6.25e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—NOTCH1—esophageal cancer	1.4e-05	6.25e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—ALDH2—esophageal cancer	1.35e-05	6.01e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—ALDOB—esophageal cancer	1.34e-05	5.99e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—EP300—esophageal cancer	1.34e-05	5.97e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—ALDH2—esophageal cancer	1.33e-05	5.96e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—GAPDH—esophageal cancer	1.29e-05	5.77e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—MYC—esophageal cancer	1.28e-05	5.74e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—GSTT1—esophageal cancer	1.28e-05	5.72e-05	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—EP300—esophageal cancer	1.28e-05	5.72e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—CRABP1—esophageal cancer	1.28e-05	5.72e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—GSTT1—esophageal cancer	1.27e-05	5.67e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—CREBBP—esophageal cancer	1.27e-05	5.67e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—CYP2A6—esophageal cancer	1.27e-05	5.66e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	1.26e-05	5.62e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—CCND1—esophageal cancer	1.26e-05	5.61e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—EGFR—esophageal cancer	1.26e-05	5.61e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—CYP2A6—esophageal cancer	1.25e-05	5.61e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	1.25e-05	5.58e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—ADH1B—esophageal cancer	1.25e-05	5.58e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—CYP1B1—esophageal cancer	1.24e-05	5.55e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—GNG7—esophageal cancer	1.22e-05	5.44e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—CDKN1A—esophageal cancer	1.22e-05	5.43e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—PTGS1—esophageal cancer	1.2e-05	5.36e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—ENO1—esophageal cancer	1.2e-05	5.36e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	1.2e-05	5.35e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—TYMP—esophageal cancer	1.19e-05	5.33e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—ENO1—esophageal cancer	1.19e-05	5.31e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—PTGS1—esophageal cancer	1.19e-05	5.31e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—PSME2—esophageal cancer	1.18e-05	5.28e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—PSME1—esophageal cancer	1.18e-05	5.28e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—PSME1—esophageal cancer	1.17e-05	5.24e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—PSME2—esophageal cancer	1.17e-05	5.24e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—CYP19A1—esophageal cancer	1.17e-05	5.22e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—CYP26A1—esophageal cancer	1.16e-05	5.19e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—EP300—esophageal cancer	1.16e-05	5.17e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—ALDH2—esophageal cancer	1.14e-05	5.1e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—EGFR—esophageal cancer	1.14e-05	5.09e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—NOS3—esophageal cancer	1.14e-05	5.07e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—ALOX15—esophageal cancer	1.13e-05	5.06e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—PIK3CA—esophageal cancer	1.09e-05	4.87e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—GSTT1—esophageal cancer	1.08e-05	4.85e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—TPI1—esophageal cancer	1.08e-05	4.82e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—GSTO1—esophageal cancer	1.08e-05	4.82e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—CYP2A6—esophageal cancer	1.07e-05	4.79e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	1.07e-05	4.77e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—HMOX1—esophageal cancer	1.07e-05	4.76e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—ERBB2—esophageal cancer	1.06e-05	4.75e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—CREBBP—esophageal cancer	1.06e-05	4.73e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—TP53—esophageal cancer	1.05e-05	4.71e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	1.05e-05	4.67e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—ALDOB—esophageal cancer	1.04e-05	4.63e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	1.02e-05	4.57e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—ABCB1—esophageal cancer	1.02e-05	4.57e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—CYP1B1—esophageal cancer	1.02e-05	4.56e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—ENO1—esophageal cancer	1.02e-05	4.54e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—PTGS1—esophageal cancer	1.02e-05	4.54e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—CYP1B1—esophageal cancer	1.01e-05	4.52e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—MYC—esophageal cancer	1.01e-05	4.5e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—PSME1—esophageal cancer	1e-05	4.48e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—PSME2—esophageal cancer	1e-05	4.48e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—GAPDH—esophageal cancer	9.96e-06	4.45e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—PIK3CA—esophageal cancer	9.88e-06	4.42e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—CRABP1—esophageal cancer	9.88e-06	4.41e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—EGFR—esophageal cancer	9.86e-06	4.4e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—CYP19A1—esophageal cancer	9.59e-06	4.29e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—CYP19A1—esophageal cancer	9.51e-06	4.25e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—NOS3—esophageal cancer	9.48e-06	4.24e-05	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—PIK3CA—esophageal cancer	9.47e-06	4.23e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—GNG7—esophageal cancer	9.39e-06	4.2e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—CCND1—esophageal cancer	9.38e-06	4.19e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—CDKN1A—esophageal cancer	9.08e-06	4.06e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—ALDH2—esophageal cancer	8.8e-06	3.93e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—HMOX1—esophageal cancer	8.75e-06	3.91e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	8.75e-06	3.91e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—HMOX1—esophageal cancer	8.68e-06	3.88e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—PTGS2—esophageal cancer	8.67e-06	3.87e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—CYP1B1—esophageal cancer	8.64e-06	3.86e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—EP300—esophageal cancer	8.64e-06	3.86e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—PIK3CA—esophageal cancer	8.55e-06	3.82e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	8.51e-06	3.8e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—ABCB1—esophageal cancer	8.4e-06	3.75e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—GSTT1—esophageal cancer	8.37e-06	3.74e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—ABCB1—esophageal cancer	8.33e-06	3.72e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—CYP2A6—esophageal cancer	8.28e-06	3.7e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—TP53—esophageal cancer	8.27e-06	3.7e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—CYP19A1—esophageal cancer	8.13e-06	3.63e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—ENO1—esophageal cancer	7.85e-06	3.51e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PTGS1—esophageal cancer	7.85e-06	3.51e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	7.74e-06	3.46e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PSME2—esophageal cancer	7.73e-06	3.45e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PSME1—esophageal cancer	7.73e-06	3.45e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—MYC—esophageal cancer	7.53e-06	3.36e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—HMOX1—esophageal cancer	7.42e-06	3.31e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—EGFR—esophageal cancer	7.36e-06	3.29e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	7.27e-06	3.25e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—EP300—esophageal cancer	7.21e-06	3.22e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—ABCB1—esophageal cancer	7.12e-06	3.18e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—CREBBP—esophageal cancer	6.84e-06	3.06e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—CYP1B1—esophageal cancer	6.67e-06	2.98e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—PIK3CA—esophageal cancer	6.39e-06	2.86e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	6.3e-06	2.81e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—CYP19A1—esophageal cancer	6.27e-06	2.8e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—TP53—esophageal cancer	6.18e-06	2.76e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—NOS3—esophageal cancer	6.12e-06	2.74e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—HMOX1—esophageal cancer	5.72e-06	2.56e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—CREBBP—esophageal cancer	5.62e-06	2.51e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—PTGS2—esophageal cancer	5.6e-06	2.5e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—CREBBP—esophageal cancer	5.57e-06	2.49e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—ABCB1—esophageal cancer	5.49e-06	2.45e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	5.38e-06	2.4e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—PIK3CA—esophageal cancer	5.33e-06	2.38e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—NOS3—esophageal cancer	5.03e-06	2.25e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—NOS3—esophageal cancer	4.98e-06	2.23e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—CREBBP—esophageal cancer	4.76e-06	2.13e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—EP300—esophageal cancer	4.66e-06	2.08e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—PTGS2—esophageal cancer	4.6e-06	2.05e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—PTGS2—esophageal cancer	4.56e-06	2.04e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—NOS3—esophageal cancer	4.26e-06	1.9e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—PTGS2—esophageal cancer	3.9e-06	1.74e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—EP300—esophageal cancer	3.82e-06	1.71e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—EP300—esophageal cancer	3.79e-06	1.69e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—CREBBP—esophageal cancer	3.67e-06	1.64e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—PIK3CA—esophageal cancer	3.45e-06	1.54e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—NOS3—esophageal cancer	3.29e-06	1.47e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—EP300—esophageal cancer	3.24e-06	1.45e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PTGS2—esophageal cancer	3.01e-06	1.34e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—PIK3CA—esophageal cancer	2.83e-06	1.26e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—PIK3CA—esophageal cancer	2.8e-06	1.25e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—EP300—esophageal cancer	2.5e-06	1.12e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—PIK3CA—esophageal cancer	2.4e-06	1.07e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PIK3CA—esophageal cancer	1.85e-06	8.26e-06	CbGpPWpGaD
